Post by : Bianca
Haleem
Regeneron Pharmaceuticals reported a robust third-quarter performance, surpassing Wall Street expectations, driven by strong demand for its blockbuster drug Dupixent. The anti-inflammatory treatment generated $4.86 billion in sales, outpacing analysts’ forecast of $4.62 billion, with the United States contributing a major share of the revenue.
The New York-based biotech firm co-develops Dupixent with France’s Sanofi, and profits from the drug are shared equally. Earlier this month, a European Medicines Agency-linked committee recommended Dupixent for adults and adolescents aged 12 and above suffering from chronic spontaneous urticaria, a skin condition marked by itchy welts and swelling. Approval in the European Union could further expand the drug’s market.
While Dupixent sales surged, Regeneron’s eye treatment Eylea faced a 28% decline in U.S. sales year-on-year, totaling $1.11 billion. The company is actively encouraging patients to switch to a higher-dose version of Eylea to counter competition from cheaper biosimilars and rival drugs.
Overall, Regeneron reported adjusted earnings per share of $11.83 on revenue of $3.75 billion, both figures surpassing Wall Street expectations. The strong quarterly performance lifted Regeneron’s shares in premarket U.S. trading.
Regeneron’s Q3 results highlight the growing reliance on Dupixent as a revenue engine, even as challenges in its eye care segment persist.
English
